Co-Diagnostics, Inc. (CODX) Stock Price & Analysis
Co-Diagnostics, Inc. (CODX) fell 10.89% to USD 4.5 as of June 10, 2026 at 02:17 UTC, according to Nexqual real-time market data.
CODX last closed at USD 5.05; the session ranged USD 4.46–5.37 on volume of 321,825 shares. Market capitalization is $16.58M, with a 52-week range of USD 1.26–46.5 (NCM). Source: Nexqual, June 10, 2026 at 02:17 UTC.
Key Statistics (as of June 10, 2026 at 02:17 UTC)
| Price | USD 4.5 |
|---|---|
| Change | ▼ 10.89% (down) |
| Previous Close | USD 5.05 |
| Open | USD 5.1 |
| Day Range | USD 4.46 – 5.37 |
| 52-Week Range | USD 1.26 – 46.5 |
| Volume | 321,825 shares |
| Market Cap | $16.58M |
| Exchange | NCM |
Technical Analysis (CODX)
Nexqual's technical model rates CODX "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 02:17 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.99 (neutral) |
| vs SMA50 | Above (USD 2.88) |
| MACD | 0.88 (positive) |
Analyst Ratings (CODX)
Wall Street analysts rate CODX "Hold", per Nexqual as of June 10, 2026 at 02:17 UTC.
| Consensus Rating | Hold |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (CODX)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -3 |
| Revenue Estimate | $133,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -4.09 vs est -3.75 ▼ miss |
| 2025-12-31 | USD -4.44 vs est -3.6 ▼ miss |
| 2025-09-30 | USD -4.66 vs est -5.7 ▲ beat |
| 2025-06-30 | USD -7.01 vs est -7.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
Financials & Fundamentals (CODX)
| Total Revenue | $718,166 |
|---|---|
| Revenue Growth (YoY) | +190.30% |
| Gross Margin | +45.06% |
| Operating Margin | -6309.12% |
| Profit Margin | +0.00% |
| ROE | -151.66% |
| Debt / Equity | 12.66 |
| Current Ratio | 2.28 |
| Total Cash | $8.23M |
| Total Debt | $2.03M |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
Financial Health Score (CODX)
Nexqual rates Co-Diagnostics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:17 UTC.
| Growth | Critical — Revenue -84% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $8M cash vs $2M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -152%, ROA -52.1% |
Ownership (CODX)
| Insider Ownership | +3.60% |
|---|---|
| Institutional Ownership | +9.53% |
| Shares Outstanding | 3.69M |
| Float | 3.50M |
| Short % of Float | +9.80% |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
Leadership (CODX)
Co-Diagnostics, Inc. is led by Dwight H. Egan (age 72), Chairman, CEO & President, per Nexqual as of June 10, 2026 at 02:17 UTC.
| Chairman, CEO & President | Dwight H. Egan (age 72) |
|---|---|
| President | Richard David Abbott (age 53) |
| CFO & Company Secretary | Brian L. Brown (age 49) |
| Chief Operating Officer | David Nielsen |
| Vice President of Finance & Accounting | Dan Bohrer |
Major Backers & Investors (CODX)
Notable institutional backers of Co-Diagnostics, Inc. include Private Advisory Group LLC, UBS Group AG, according to Nexqual as of June 10, 2026 at 02:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Private Advisory Group LLC | 1.83% |
| UBS Group AG | 0.33% |
Source: Nexqual, June 10, 2026 at 02:17 UTC.
From Co-Diagnostics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
- It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
- The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus.
- In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VXRT | Vaxart, Inc. | USD 0.58 | ▼ 6.45% |
| APT | Alpha Pro Tech, Ltd. | USD 5.37 | ▲ 4.68% |
| VIR | Vir Biotechnology, Inc. | USD 8.51 | ▼ 1.62% |
| IBIO | iBio, Inc. | USD 1.7 | ▼ 6.59% |
| INO | Inovio Pharmaceuticals, Inc. | USD 1.1 | ▲ 2.8% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:17 UTC. This page is informational and not investment advice.